Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Non Operating Income (2016 - 2026)

Gyre Therapeutics has reported Non Operating Income over the past 15 years, most recently at -$2.2 million for Q4 2025.

  • Quarterly Non Operating Income fell 34.27% to -$2.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.5 million through Dec 2025, up 9.28% year-over-year, with the annual reading at -$1.5 million for FY2025, 9.28% up from the prior year.
  • Non Operating Income was -$2.2 million for Q4 2025 at Gyre Therapeutics, down from $727000.0 in the prior quarter.
  • Over five years, Non Operating Income peaked at $727000.0 in Q3 2025 and troughed at -$2.2 million in Q4 2025.
  • The 5-year median for Non Operating Income is -$18500.0 (2021), against an average of -$232444.4.
  • The largest YoY upside for Non Operating Income was 3600.0% in 2023 against a maximum downside of 133200.0% in 2023.
  • A 5-year view of Non Operating Income shows it stood at -$20000.0 in 2021, then soared by 95.0% to -$1000.0 in 2022, then tumbled by 23600.0% to -$237000.0 in 2023, then crashed by 589.45% to -$1.6 million in 2024, then plummeted by 34.27% to -$2.2 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Non Operating Income are -$2.2 million (Q4 2025), $727000.0 (Q3 2025), and -$145000.0 (Q2 2025).